PQQ (Pyrroloquinoline Quinone) — Safety, Research, Risks & Legal Status

Not medical advice. PQQ (Pyrroloquinoline Quinone) is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Methoxatin; BioPQQ; PQQ disodium salt; pyrroloquinoline quinone disodium salt
Category	Supplement
Chemical class	Redox-active ortho-quinone cofactor
Production method	Bacterial fermentation (Hyphomicrobium denitrificans CK-275); BioPQQ grade is ≥99.0% purity
FDA regulatory status	GRAS under GRN 000641, 000701, 000709; dietary supplement ingredient; not an approved drug
Human trial count	Approximately 12 published clinical trials as of available literature; doses up to 100 mg/day, durations up to 24 weeks
Key glucometer interaction	Interferes with GDH-PQQ based glucose meters, causing falsely elevated readings; significant risk in dialysis patients on insulin
NOAEL (rat, 90-day)	100 mg/kg bw/day; estimated human safety ceiling approximately 240 mg/day for a 60 kg adult using 100x safety margin
US legal status	Legal in the United States as a dietary supplement ingredient and food additive. FDA has issued multiple GRAS (Generally Recognized as Safe) notices for pyrroloquinoline quinone disodium salt (GRN 000641, GRN 000701, GRN 000709), permitting use in energy/sport drinks (up to 5 mg/serving) and fortified water (up to 20 mg/serving). Structure/function claims (mitochondrial support, antioxidant protection) are permitted on supplement labels. PQQ is not approved as a pharmaceutical drug by the FDA or EMA for any indication. No controlled substance scheduling applies.

What is PQQ (Pyrroloquinoline Quinone)?

PQQ (pyrroloquinoline quinone) is a redox-active quinone cofactor produced by bacterial fermentation (typically Hyphomicrobium denitrificans CK-275) and commercially available as the disodium salt at ≥99.0% purity. It is classified as a dietary supplement ingredient, not a drug. Chemically, PQQ functions as an electron carrier capable of cycling between oxidized and reduced states, acting as a cofactor for certain oxidative enzymes. It is found in trace quantities in some foods. The branded pharmaceutical-grade form, BioPQQ, is manufactured primarily by Zhejiang Hisun Pharmaceutical. Human clinical data are limited in scope and duration; the most robust evidence base is preclinical and animal-derived.

How it works

PQQ operates through several intersecting pathways. As a redox-cycling quinone, it scavenges reactive oxygen species (ROS) with potency reportedly many-fold greater than ascorbic acid, catalyzing electron transfer at picomolar concentrations while generating micromolar amounts of reduced product. In cell culture and animal models, PQQ activates the SIRT1/PGC-1α signaling axis and CREB phosphorylation, which drives expression of nuclear respiratory factors NRF1 and NRF2 and upregulates SIRT3 - converging on mitochondrial biogenesis and enhanced ATP synthesis capacity. Anti-inflammatory activity has been attributed to modulation of NF-κB and MAPK pathways in preclinical systems. The mitochondrial biogenesis effect is well-characterized in vitro and in rodent models; direct evidence in humans remains preliminary.

Background & history

PQQ was first identified as a cofactor for bacterial methanol dehydrogenase and was historically designated "methoxatin." Early research, largely pioneered by Mitsubishi Gas Chemical in Japan, established its biochemical properties as a quinone cofactor. The discovery that PQQ stimulates mitochondrial biogenesis in mammals - published in landmark papers around 2010 - drove commercial interest in its supplementation potential. Regulatory commercialization followed: FDA GRAS notices were granted across multiple applications through the 2010s-2020s, and the compound entered global supplement markets. It is now one of the more heavily researched mitochondrial supplement ingredients, though it has not entered pharmaceutical drug development pipelines.

What the research says

Human evidence is limited but growing. Approximately twelve published clinical trials have been conducted, with doses up to 100 mg/day for up to 24 weeks; no serious adverse events have been reported in these trials. A 64-subject RCT conducted in Japan over 12 weeks found modest improvements in lower-limb extension muscle strength and grip strength with PQQ supplementation. Open-label studies have reported improvements in subjective sleep quality and cognitive function in older adults with age-related decline, though open-label data carry significant limitations. A single-dose pharmacodynamic study (0.2 mg/kg) demonstrated significant reduction in TBARS, an oxidative stress biomarker. Notably, published human trials have not demonstrated efficacy for insulin sensitivity, blood glucose control, or body weight. Two trials were ongoing as of 2024-2025: NCT07148726 examining metabolic and exercise outcomes in non-endurance athletes, and NCT06748989 examining cognitive endpoints in postmenopausal women using a multi-ingredient formula containing PQQ. Preclinical and animal evidence for mitochondrial biogenesis and antioxidant activity is robust. Human evidence should be characterized as preliminary and mostly short-term (under 6 months).

Reported effects

Antioxidant activity - ROS scavenging demonstrated in human biomarker study (TBARS reduction at 0.2 mg/kg single dose); robust in preclinical models
Mitochondrial biogenesis - well-established in cell culture and animal models via SIRT1/PGC-1alpha/CREB signaling; human evidence is preliminary
Muscle strength - modest improvements in lower-limb extension and grip strength observed in one 64-subject RCT (12 weeks, Japan); not replicated at scale
Sleep quality improvement - reported in open-label studies in older adults; no blinded RCT confirmation
Cognitive function support in age-related decline - open-label data only; limited and inconclusive
No demonstrated effect on insulin sensitivity, blood glucose, or body weight in published human trials

Dosing & administration (informational)

Published human clinical trials have used doses ranging from approximately 10 mg to 100 mg per day, with durations up to 24 weeks. A single-dose pharmacokinetic/pharmacodynamic study used 0.2 mg/kg. FDA GRAS approvals cover specific food-use scenarios (up to 5 mg/serving in energy drinks, up to 20 mg/serving in fortified water). These figures are provided for informational reference from the published literature only and do not constitute a dosing recommendation or clinical protocol. Appropriate dosing for any individual should be determined in consultation with a qualified clinician or registered dietitian.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No systemic toxicity or genotoxicity observed in animal studies or the published human trial literature
NOAEL (no-observed-adverse-effect-level) established at 100 mg/kg bw/day in 90-day rat studies; applying a 100x safety margin yields an estimated human ceiling of approximately 240 mg/day for a 60 kg adult - this is a regulatory estimation, not a clinical dosing target
Mild transient GI effects (nausea, stomach discomfort, bloating) reported rarely; typically resolve with continued use
Occasional headache or insomnia reported in a small subset of users in post-market reports
CRITICAL INTERACTION: PQQ interferes with glucose dehydrogenase-PQQ (GDH-PQQ) based glucometers, causing falsely elevated glucose readings; this creates a serious risk of inappropriate insulin dosing, particularly in end-stage renal disease and dialysis patients - such patients should not use PQQ-based test strips or should inform clinicians of PQQ supplementation
Long-term human safety data beyond 24 weeks is not available; absence of observed harm in short trials does not confirm long-term safety

Drug & supplement interactions

T
h
e
m
o
s
t
c
l
i
n
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
i
n
t
e
r
a
c
t
i
o
n
i
s
w
i
t
h
G
D
H
-
P
Q
Q
(
g
l
u
c
o
s
e
d
e
h
y
d
r
o
g
e
n
a
s
e
p
y
r
r
o
l
o
q
u
i
n
o
l
i
n
e
q
u
i
n
o
n
e
)
b
a
s
e
d
b
l
o
o
d
g
l
u
c
o
s
e
m
o
n
i
t
o
r
i
n
g
d
e
v
i
c
e
s
.
P
Q
Q
c
a
n
a
c
t
a
s
a
n
a
l
t
e
r
n
a
t
i
v
e
e
l
e
c
t
r
o
n
a
c
c
e
p
t
o
r
f
o
r
G
D
H
-
P
Q
Q
e
n
z
y
m
e
s
y
s
t
e
m
s
i
n
t
h
e
s
e
m
e
t
e
r
s
,
p
r
o
d
u
c
i
n
g
f
a
l
s
e
l
y
e
l
e
v
a
t
e
d
g
l
u
c
o
s
e
r
e
a
d
i
n
g
s
i
n
d
e
p
e
n
d
e
n
t
o
f
a
c
t
u
a
l
b
l
o
o
d
g
l
u
c
o
s
e
.
T
h
i
s
i
n
t
e
r
a
c
t
i
o
n
c
a
r
r
i
e
s
s
e
r
i
o
u
s
c
l
i
n
i
c
a
l
r
i
s
k
-
p
a
r
t
i
c
u
l
a
r
l
y
f
o
r
p
a
t
i
e
n
t
s
w
i
t
h
e
n
d
-
s
t
a
g
e
k
i
d
n
e
y
d
i
s
e
a
s
e
o
r
o
n
d
i
a
l
y
s
i
s
w
h
o
m
a
y
u
s
e
t
h
e
s
e
m
e
t
e
r
s
a
n
d
r
e
s
p
o
n
d
w
i
t
h
i
n
s
u
l
i
n
d
o
s
i
n
g
.
P
a
t
i
e
n
t
s
o
n
i
n
s
u
l
i
n
t
h
e
r
a
p
y
s
h
o
u
l
d
v
e
r
i
f
y
t
h
e
i
r
g
l
u
c
o
m
e
t
e
r
d
o
e
s
n
o
t
u
s
e
G
D
H
-
P
Q
Q
t
e
c
h
n
o
l
o
g
y
b
e
f
o
r
e
u
s
i
n
g
P
Q
Q
s
u
p
p
l
e
m
e
n
t
s
.
N
o
w
e
l
l
-
c
h
a
r
a
c
t
e
r
i
z
e
d
d
r
u
g
-
d
r
u
g
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
i
n
t
e
r
a
c
t
i
o
n
s
a
r
e
d
o
c
u
m
e
n
t
e
d
i
n
t
h
e
p
u
b
l
i
s
h
e
d
h
u
m
a
n
l
i
t
e
r
a
t
u
r
e
,
t
h
o
u
g
h
t
h
e
h
u
m
a
n
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
s
p
a
r
s
e
.
T
h
e
a
n
t
i
o
x
i
d
a
n
t
a
n
d
m
i
t
o
c
h
o
n
d
r
i
a
l
a
c
t
i
v
a
t
i
o
n
p
r
o
p
e
r
t
i
e
s
a
r
e
t
h
e
o
r
e
t
i
c
a
l
l
y
r
e
l
e
v
a
n
t
t
o
c
o
n
s
i
d
e
r
a
t
i
o
n
s
a
r
o
u
n
d
c
o
n
c
u
r
r
e
n
t
u
s
e
w
i
t
h
m
i
t
o
c
h
o
n
d
r
i
a
l
-
a
f
f
e
c
t
i
n
g
d
r
u
g
s
o
r
o
t
h
e
r
a
n
t
i
o
x
i
d
a
n
t
s
u
p
p
l
e
m
e
n
t
s
,
b
u
t
n
o
c
o
n
t
r
o
l
l
e
d
d
a
t
a
e
x
i
s
t
i
n
t
h
i
s
d
o
m
a
i
n
.

Who should avoid it

Patients using GDH-PQQ based glucometers, particularly those on insulin or with end-stage kidney disease
Individuals with known hypersensitivity to any component of PQQ disodium salt formulations
Pregnant or breastfeeding individuals - no safety data in these populations
Concurrent use with insulin therapy requires glucometer compatibility verification before supplementing

How it is commonly combined

PQQ is frequently combined with CoQ10 in commercial formulations, with the rationale that CoQ10 supports the electron transport chain while PQQ may stimulate mitochondrial biogenesis - these are complementary mechanistic targets. This combination has not been studied in controlled human trials to a sufficient standard to draw efficacy conclusions. PQQ has also been formulated with GABA, caffeine, and B-vitamins in at least one ongoing clinical trial (NCT06748989) evaluating cognitive endpoints in postmenopausal women; results are not yet available. No combination stacking protocol has established human evidence of additive or synergistic benefit as of available literature.

Legal & regulatory. Legal in the United States as a dietary supplement ingredient and food additive. FDA has issued multiple GRAS (Generally Recognized as Safe) notices for pyrroloquinoline quinone disodium salt (GRN 000641, GRN 000701, GRN 000709), permitting use in energy/sport drinks (up to 5 mg/serving) and fortified water (up to 20 mg/serving). Structure/function claims (mitochondrial support, antioxidant protection) are permitted on supplement labels. PQQ is not approved as a pharmaceutical drug by the FDA or EMA for any indication. No controlled substance scheduling applies.

Quality & harm reduction

T
h
e
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
b
r
a
n
d
e
d
f
o
r
m
B
i
o
P
Q
Q
(
m
a
n
u
f
a
c
t
u
r
e
d
b
y
Z
h
e
j
i
a
n
g
H
i
s
u
n
P
h
a
r
m
a
c
e
u
t
i
c
a
l
)
i
s
p
r
o
d
u
c
e
d
v
i
a
b
a
c
t
e
r
i
a
l
f
e
r
m
e
n
t
a
t
i
o
n
w
i
t
h
d
o
c
u
m
e
n
t
e
d
p
u
r
i
t
y
s
p
e
c
i
f
i
c
a
t
i
o
n
s
o
f
≥
9
9
.
0
%
a
n
d
h
a
s
b
e
e
n
r
e
v
i
e
w
e
d
b
y
F
D
A
u
n
d
e
r
m
u
l
t
i
p
l
e
G
R
A
S
n
o
t
i
c
e
s
.
U
n
b
r
a
n
d
e
d
b
u
l
k
P
Q
Q
f
r
o
m
c
o
m
m
o
d
i
t
y
s
u
p
p
l
e
m
e
n
t
s
u
p
p
l
i
e
r
s
l
a
c
k
s
t
h
i
s
r
e
g
u
l
a
t
o
r
y
b
a
c
k
s
t
o
p
;
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
-
o
f
-
a
n
a
l
y
s
i
s
v
e
r
i
f
i
c
a
t
i
o
n
i
s
a
d
v
i
s
a
b
l
e
.
T
h
e
c
o
m
p
o
u
n
d
i
s
r
e
l
a
t
i
v
e
l
y
s
t
a
b
l
e
a
n
d
a
n
a
l
y
t
i
c
a
l
l
y
c
h
a
r
a
c
t
e
r
i
z
a
b
l
e
,
s
o
a
d
u
l
t
e
r
a
t
i
o
n
i
s
l
e
s
s
o
f
a
c
o
n
c
e
r
n
t
h
a
n
w
i
t
h
p
e
p
t
i
d
e
o
r
b
o
t
a
n
i
c
a
l
i
n
g
r
e
d
i
e
n
t
s
,
b
u
t
p
u
r
i
t
y
s
t
a
n
d
a
r
d
s
v
a
r
y
a
c
r
o
s
s
m
a
n
u
f
a
c
t
u
r
e
r
s
.

Safer, legal alternative we recommend

Sleepio Formula. For the same sleep goal, our Sleep Formula is a legal, non-prescription option you can buy now.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What dose of PQQ should I take?

This is a question for your clinician or registered dietitian. Published human trials have used a range of approximately 10-100 mg/day for periods up to 24 weeks, but those are research parameters, not clinical recommendations. The appropriate amount for any individual depends on health status, goals, and concurrent medications - none of which can be evaluated here.

Does PQQ actually stimulate mitochondrial biogenesis in humans?

The mitochondrial biogenesis effect is well-established in cell culture and animal models, where PQQ activates SIRT1/PGC-1alpha and CREB signaling. Direct evidence in humans is limited. Human trials have shown some biomarker changes (oxidative stress reduction) and modest functional outcomes (muscle strength in one RCT), but controlled evidence specifically confirming mitochondrial biogenesis in living humans at supplement doses has not been published.

Is PQQ a vitamin?

PQQ has been studied as a potential B-vitamin candidate, but this designation is not established. It is not classified as a vitamin in any regulatory framework. It is classified as a dietary supplement ingredient and food additive in the US. The 'vitamin' framing sometimes used in popular media is not supported by the regulatory or mainstream scientific literature.

Can PQQ be used by people with diabetes?

This requires clinician guidance. The critical concern is that PQQ interferes with GDH-PQQ based blood glucose meters, which can produce falsely elevated glucose readings. For anyone using insulin, an incorrect reading could result in inappropriate dosing. People with diabetes, especially those on dialysis or with kidney disease, should consult their clinician and verify glucometer compatibility before using PQQ supplements.

Is the cognitive benefit from PQQ real?

Human evidence for cognitive benefits is preliminary and methodologically limited. Available studies are mostly open-label (unblinded) and conducted in older adults reporting subjective changes in cognitive function and sleep quality. Without placebo-controlled blinded trials specifically powered for cognitive endpoints, the cognitive benefit claim cannot be considered established. Two clinical trials with cognitive or performance endpoints were ongoing as of 2024-2025 (NCT07148726, NCT06748989); their results may provide better data.

Is PQQ the same thing that is found naturally in food?

PQQ has been detected in trace quantities in various foods including fermented soybeans (natto), green pepper, kiwi fruit, and human breast milk, though dietary intake from food sources is orders of magnitude lower than supplement doses used in trials. The supplement form is produced via bacterial fermentation rather than food extraction.

References & further reading

PubMed: pyrroloquinoline quinone mitochondrial biogenesis SIRT1 PGC-1alpha (see PMID 19861415, PMID 28074796)
PubMed: pyrroloquinoline quinone clinical trial humans safety efficacy muscle cognitive
PubMed: pyrroloquinoline quinone GRAS safety toxicology NOAEL (see PMC7010138 - EFSA novel food assessment)
ClinicalTrials.gov: NCT07148726 - Effects of Pyrroloquinoline Quinone Supplementation on Non-Endurance Trained Athletes (2024-ongoing)
ClinicalTrials.gov: NCT06748989 - Cognitive Effects of a Dietary Supplement With PQQ, GABA, Caffeine, and B-Vitamins in Healthy Postmenopausal Women (2024-ongoing)